BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update
29 avr. 2020 06h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority
03 avr. 2020 06h58 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer
01 avr. 2020 09h00 HE
|
BrainStorm Cell Therapeutics Inc.
International Pharmaceutical Veteran to Lead Global Business and Commercial Development Ralph Kern, MD, MHSc, Promoted to President NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell...
BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors
31 mars 2020 04h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced the...
BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19
16 mars 2020 03h00 HE
|
BrainStorm Cell Therapeutics Inc.
Funding Secured and Senior Management Team Activated by CEO to Ensure Advancement of all Operational Activities and Completion of Corporate Clinical Milestones Call Time: Wednesday, March...
BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share
06 mars 2020 09h25 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has...
Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial
27 févr. 2020 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and BOSTON, Feb. 27, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019
18 févr. 2020 07h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces...
BrainStorm’s Chief Operating Officer to Present at Noble Capital Markets’ Sixteenth Annual Investor Conference
17 févr. 2020 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 17, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases,...
BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS
11 févr. 2020 06h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...